Sepsis Market Professional Industry Research Report 2025

June 29 04:36 2021
Sepsis Market Professional Industry Research Report 2025

DelveInsight’s ‘Sepsis Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Request a Free Sample to know about the report-


Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis can be the clinical manifestation of infections acquired both in the community setting and in health care facilities.


Sepsis Market: Report

The Sepsis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Sepsis market size from 2018 to 2030. The Report also covers current Sepsis treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.


Major Key Players of Sepsis Market Report

  • La Jolla Pharmaceuticals
  • Par Pharmaceutical
  • Ono Pharmaceutical
  • Vivacelle Bio
  • Inotrem
  • Enlivex Therapeutics
  • Adrenomed
  • Shionogi
  • Asahi Kasei Pharma Corp.
  • AM-Pharma
  • ABIONYX Pharma
  • Revimmune
  • Baxter Healthcare Corporation
  • BioMarck Pharmaceuticals
  • And many others


Regions Analysis of:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Sepsis Diagnosis

Diagnosis of Sepsis is a differential exercise, where Sepsis suspicion is easily assessed, but confirmation in terms of positive infection and determination of organ dysfunction remains challenging. Two diagnostic criteria are being used more extensively to identify septic patients in the current scenario, namely SIRS and SOFA, where qSOFA is used as a screening tool to identify patients with increased mortality risk.


Sepsis Market: Treatment

Sepsis is a medical emergency; in other words, Sepsis should be treated as quickly and efficiently as possible. Treatment for Sepsis varies, depending on the site and cause of the initial infection, the organs affected, and the extent of any damage. If the patient is diagnosed with Sepsis, the patient is then immediately taken to the hospital. If Sepsis is left untreated, it can lead to septic shock or death in some cases. Sepsis treatment is generally examined under two main headings: appropriate antimicrobial treatment and all-purpose supporting treatment. The treatment for Sepsis includes several antibiotics to fight infection, vasoactive medications to increase blood pressure, insulin to stabilize blood sugar, and painkillers. In severe cases of Sepsis, extracorporeal therapies are also used.


Sepsis Market: Symptoms

The symptoms of Sepsis include fever or low temperature and shivering, altered mental status, difficulty breathing/rapid breathing, increased heart rate, weak pulse/low blood pressure, low urine output, cyanotic or mottled skin, cold extremities, and extreme body pain or discomfort.


Sepsis Market: Insights

Sepsis is a medical emergency; in other words, Sepsis should be treated as quickly and efficiently as possible. Treatment for Sepsis varies, depending on the site and cause of the initial infection, the organs affected, and the extent of any damage.


Sepsis Market: Emerging Drugs

VBI-S: Vivacelle Bio

Vivacelle Bio’s lead candidate, VBI-S is made of small particles of specific lipid called micelles and liposomes to treat hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the ’body’s fluid volume in hypovolemic shock, due to Sepsis, from non-survival to survival. In July 2019, the company announced US FDA clearance to enroll patients into a Phase IIa clinical trial of VBI-S to elevate blood pressure in subjects who have shock due to Sepsis. The therapy is currently under Phase II clinical evaluation to treat hypovolemia due to Sepsis/septic shock (Vivacelle Bio Inc., n.d.).

Allocetra: Enlivex Therapeutics

Allocetra is being developed by Enlivex Therapeutics as adjunctive therapy for preventing organ failure and mortality in Sepsis, in combination with existing antibiotics agents. It is designed to offer a true paradigm shift in the quest to solve a complex healthcare challenge. The drug is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The diseases such as solid cancers, Sepsis, COVID-19, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy, or in combination with leading therapeutic agents (Enlivex, n.d.).


Sepsis Market: Outlook

According to the World Health Organization (WHO), Sepsis is a syndromic response to infection and is frequently a final common pathway to death from many infectious diseases worldwide. The most important concern in Sepsis is a quick diagnosis and prompt treatment. Patients diagnosed with severe Sepsis are usually placed in the intensive care unit (ICU) of the hospital for special treatment.


Table of Content

1. Key Insights

2. Report Introduction

3. Sepsis Market Overview at a Glance

4. Executive Summary of Sepsis

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Patient Journey

8. Organizations contributing towards Sepsis

9. Marketed Therapies

10. Emerging Therapies

11. Sepsis: Seven Major Market Analysis

12. Seven Major Market Outlook

13. KOL Views

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Reimbursement and Market Access

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight


Sepsis Market: Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the Sepsis market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Sepsis. The launch of emerging therapies will significantly impact the Sepsis market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author